+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

UPLIFT Study: the effects of long-term therapy with inhaled tiotropium in chronic obstructive pulmonary disease. Evaluation of: Tashkin DP, Celli B, Senn S et al.: a 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med (2008) 359(15):1543-1554



UPLIFT Study: the effects of long-term therapy with inhaled tiotropium in chronic obstructive pulmonary disease. Evaluation of: Tashkin DP, Celli B, Senn S et al.: a 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med (2008) 359(15):1543-1554



Expert Opinion on PharmacoTherapy 10(4): 719-722



In chronic obstructive pulmonary disease (COPD), inhaled tiotropium bromide, a long-acting anticholinergic, has been shown to exert a sustained bronchodilator effect and to be superior to ipratropium bromide, a short-acting formulation of the same pharmacological class. To discuss the effects of long-term therapy with tiotropium in COPD. Analysis of efficacy and safety data on tiotropium from a 4-year randomized placebo controlled study performed in moderate to very severe COPD patients. Tiotropium was found to reduce significantly COPD-related morbidity, to improve health-related quality of life (HRQoL) irrespective of disease severity and to slow significantly lung function decline in patients not using inhaled corticosteroids or other long-acting bronchodilators. The safety profile -- and in particular cardiovascular safety -- of tiotropium was good. Tiotropium bromide, alone or in combination with other inhaled therapies, can maintain an adequate control of COPD on a long-term basis.

(PDF emailed within 0-6 h: $19.90)

Accession: 056731252

Download citation: RISBibTeXText

PMID: 19284368

DOI: 10.1517/14656560902740804


Related references

Tiotropium therapy and mortality risk in COPD patients: the most severe, the most protected? Evaluation of Celli B, Decramer M, Kesten S, et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180(10): 948-55. Expert Opinion on PharmacoTherapy 11(8): 1439-1441, 2010

A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. European Respiratory Journal 19(2): 217-224, 2002

Triple inhaled therapy in stable chronic obstructive pulmonary disease: the earlier, the better? Evaluation of Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180:741-50. Expert Opinion on PharmacoTherapy 11(6): 1039-1042, 2010

Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 180(10): 948-955, 2009

A 4-year trial of tiotropium in chronic obstructive pulmonary disease (UPLIFT trial). Revista Portuguesa de Pneumologia 15(1): 137-140, 2009

Combination inhaled steroid and long-acting beta(2)-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2011(3): Cd008532, 2011

Combination inhaled steroid and long-acting beta₂-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2016(6): Cd008532, 2016

Impact of tiotropium on the course of moderate-to-very severe chronic obstructive pulmonary disease: the UPLIFT trial. Expert Review of Respiratory Medicine 4(3): 279-289, 2010

Short-term effects of inhalative tiotropium/formoterol/budenoside versus tiotropium/formoterol in patients with newly diagnosed chronic obstructive pulmonary disease requiring surgery for lung cancer: a prospective randomized trial. European Journal of Cardio-Thoracic Surgery 39(6): 995-1000, 2012

Observational study on the impact of initiating tiotropium alone versus tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary disease. Respiratory Research 13: 15, 2012

Four-year trial of tiotropium in chronic obstructive pulmonary disease. Canadian Family Physician Medecin de Famille Canadien 58(8): 848-849, 2012

A 4-year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal of Medicine 359(15): 1543-1554, 2008

Tiotropium: An inhaled, long-acting anticholinergic drug for chronic obstructive pulmonary disease. Pharmacotherapy 23(2): 183-189, 2003

Effects of inhaled tiotropium on left ventricular diastolic function in chronic obstructive pulmonary disease patients after pulmonary resection. Annals of Thoracic and Cardiovascular Surgery 18(3): 206-211, 2013

Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy. European Journal of Health Economics 13(1): 71-80, 2012